Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-05-14-Speech-2-282"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20020514.12.2-282"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:translated text |
".
Mr President, Mr Whitehead, the Commission has indeed acknowledged, in the action plan on life sciences and biotechnology published on 23 January 2002, that this area requires us to take into account both ethical and economic, even industrial considerations. The Commission is convinced that we can and must reconcile these two dimensions, including in the area of genetic and pharmacogenomic testing.
In practice, this involves, first and foremost, identifying and analysing the ethical, legal and social implications as early as possible in the development phases and before the technologies are widely applied. It is important to encourage ethics experts, lawyers and sociologists to work closely with scientists and manufacturers, in order to encourage their mutual education and a dialogue involving the main players, including patients, political decision-makers and the public in the widest sense. These initiatives will be included in the objectives of the Sixth Framework Programme for research, particularly under the first priority thematic area of ‘Genomics and biotechnology for health’.
Secondly, we wish to continue to stimulate research into ethics in order to increase knowledge and further understanding of the various approaches at European level.
Thirdly, we want to develop a legal and regulatory framework for biotechnology, concerning, in particular, genetic tests, which is based on a broad social consensus which can only be achieved through open, two-way communication."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples